As-needed dosing is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-06-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
From a pharmacokinetic standpoint, the peptide is usually delivered by injection because oral bioavailability is very low; proteases in the digestive tract degrade it rapidly. After subcutaneous administration, plasma concentrations reach a peak within roughly one hour. Its elimination half-life is relatively short, with most reports placing it in the range of a few hours. Nasal formulations have also been examined, though absorption varies widely between individuals. Metabolism proceeds mainly through peptidase cleavage, and the resulting products are excreted by the kidneys.
PT-141 initiates cellular signaling by binding to specific subtypes within the melanocortin receptor family. These receptors belong to the G protein-coupled receptor superfamily, and activation raises intracellular cyclic adenosine monophosphate levels. This cascade ultimately influences neuronal circuits in the central nervous system that are associated with sexual desire and arousal. Research indicates the compound's action concentrates in hypothalamic regions rather than peripheral tissues, which helps explain some observed pharmacological features. The selectivity of receptor binding underlies its functional differences.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Cyclic heptapeptide | Synthetic analogue of alpha-MSH |
| Molecular formula | C50H68N14O10 | Acetate salt form commonly reported |
| Molecular mass | ~1025 Da | Monoisotopic value near 1025.2 |
| Key structural motif | Lactam bridge | Asp side chain to Lys side chain |
| Solid appearance | White to off-white powder | Lyophilised and hygroscopic |
After subcutaneous dosing, peak plasma concentrations appear within roughly one hour, and elimination is fast, with a half-life on the order of a few hours. Degradation is mainly proteolytic, and at least one circulating fragment retains receptor activity, so parent-drug levels alone do not describe total exposure. Clearance does not depend heavily on hepatic cytochrome enzymes, which lowers the likelihood of common metabolic interaction routes. Data in renal or hepatic impairment are limited. Repeated dosing does not appear to produce marked accumulation given the short half-life.
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
Lyophilized peptide material is generally stored at -20 °C or below to limit degradation, while reconstituted solutions are less stable and are typically kept refrigerated and protected from light. Repeated freeze-thaw cycles can accelerate aggregation and should be minimized. Stability for any specific lot depends on purity, moisture content, and packaging. Handling in a temperature-controlled environment reduces variability across replicates, and exposure to ambient humidity during weighing can introduce error. Aliquotting reduces the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard method for assessing purity. Mass spectrometry confirms molecular identity and detects sequence variants or truncation products. Ultraviolet absorbance at 214 or 280 nm is used for quantification, with the choice depending on the peptide sequence. Method validation typically addresses linearity, limit of detection, and precision across a defined concentration range. Impurity profiling may also employ ion-exchange or size-exclusion chromatography, and these techniques complement one another.
== Personal life == Carlisle grew up in Craigieburn, a northern suburb of Melbourne. He is the second youngest of five children and has four sisters. He attended Willmott Park Primary School in Craigieburn before going to Niddrie Secondary College. Carlisle has several tattoos. He has an ambigram tattoo of "mother" and "Darlene" on his arm, "Carlisle" on the right side of his back and his sisters' names on his ribs.
=== Topical antifungal === Topically administered ketoconazole is usually prescribed for fungal infections of the skin and mucous membranes, such as athlete's foot, ringworm, candidiasis (yeast infection or thrush), jock itch, and tinea versicolor. Topical ketoconazole is also used as a treatment for dandruff (seborrheic dermatitis of the scalp) and for seborrheic dermatitis on other areas of the body, perhaps acting in these conditions by suppressing levels of the fungus Malassezia furfur on the skin.
Wingstop Inc. is an American international fast food chain that primarily sells buffalo wings. The restaurant chain was founded in 1994 in Garland, Texas, and began offering franchises in 1997. As of 2026, Wingstop had over 3,000 restaurants in the world. The chain is headquartered in Dallas, Texas. In 2003, the chain was acquired by Gemini Investors, which sold it to Roark Capital Group in 2010. Wingstop went public in 2015.
== Function == YAP1 is a transcriptional co-activator and its proliferative and oncogenic activity is driven by its association with the TEAD family of transcription factors, which up-regulate genes that promote cell growth and inhibit apoptosis. Several other functional partners of YAP1 were identified, including RUNX, SMADs, p73, ErbB4, TP53BP2, LATS1/2, PTPN14, AMOTs, and ZO1/2. YAP1 and its close paralog, TAZ (WWTR1), are the main effectors of the Hippo tumor suppressor pathway. When the pathway is activated, YAP1 and TAZ are phosphorylated on a serine residue and sequestered in the cytoplasm by 14-3-3 proteins. When the Hippo pathway is not activated, YAP1/TAZ enter the nucleus and regulate gene expression. It is reported that several genes are regulated by YAP1, including Birc2, Birc5, connective tissue growth factor (CTGF), amphiregulin (AREG), Cyr61, Hoxa1 and Hoxc13. YAP/TAZ have also been shown to act as stiffness sensors, regulating mechanotransduction independently of the Hippo signalling cascade. As YAP and TAZ are transcriptional co-activators, they do not have DNA-binding domains. Instead, when inside the nucleus, they regulate gene expression through TEAD1-4 which are sequence-specific transcription factors that mediate the main transcriptional output of the Hippo pathway. The YAP/TAZ and TEAD interaction competitively inhibits and actively dissociates the TEAD/VGLL4 interaction which functions as a transcriptional repressor.
==== Empyema ==== Untreated cholecystitis can lead to worsened inflammation and infected bile that can lead to a collection of pus inside the gallbladder, also known as empyema. The symptoms of empyema are similar to uncomplicated cholecystitis but greater severity: high fever, severe abdominal pain, more severely elevated white blood count.
Sources: en.wikipedia.org
== Applications == Pyrolysis is most commonly used in the treatment of organic materials. It is one of the processes involved in the charring of wood. In general, pyrolysis of organic substances produces volatile products and leaves char, a carbon-rich solid residue. Extreme pyrolysis, which leaves mostly carbon as the residue, is called carbonization. Pyrolysis is considered one of the steps in the processes of gasification or combustion. Compared to syngas, pyrolysis gas has a high percentage of heavy tar fractions, which condense at relatively high temperatures, preventing its direct use in gas burners and internal combustion engines. The process is used heavily in the chemical industry, for example, to produce ethylene, many forms of carbon, and other chemicals from petroleum, coal, and even wood, or to produce coke from coal. It is used also in the conversion of natural gas (primarily methane) into hydrogen gas and solid carbon char, recently introduced on an industrial scale. Aspirational applications of pyrolysis would convert biomass into syngas and biochar, waste plastics back into usable oil, or waste into safely disposable substances.
=== Private members === Private members include individuals such as researchers, scientists, industrial practitioners, journalists or professors with extensive expertise, passion or active in fields related to the refrigeration sector.
==== G ==== Goji, the fruit of Lycium barbarum – is usually sold in open boxes and small packages in dried form, and is traditionally cooked before consumption. The fruit is preserved by drying them in full sun on open trays or by mechanical dehydration employing a progressively increasing series of heat exposure over 48 hours. Gotgam (dried persimmon) Guajillo chili – a dried type of mirasol chili pepper.
==== Chemistry ==== UV/Vis spectroscopy is widely used as a technique in chemistry to analyze chemical structure, the most notable one being conjugated systems. UV radiation is often used to excite a given sample where the fluorescent emission is measured with a spectrofluorometer. In biological research, UV radiation is used for quantification of nucleic acids or proteins. In environmental chemistry, UV radiation could also be used to detect Contaminants of emerging concern in water samples. In pollution control applications, ultraviolet analyzers are used to detect emissions of nitrogen oxides, sulfur compounds, mercury, and ammonia, for example in the flue gas of fossil-fired power plants. Ultraviolet radiation can detect thin sheens of spilled oil on water, either by the high reflectivity of oil films at UV wavelengths, fluorescence of compounds in oil, or by absorbing of UV created by Raman scattering in water. UV absorbance can also be used to quantify contaminants in wastewater. Most commonly used 254 nm UV absorbance is generally used as a surrogate parameters to quantify NOM. Another form of light-based detection uses an excitation-emission matrix (EEM) to detect and identify contaminants based on their fluorescence properties. EEM could be used to discriminate different groups of NOM based on the difference in light emission and excitation of fluorophores. NOMs with certain molecular structures are reported to have fluorescent properties in a wide range of excitation/emission wavelengths.
Sources: en.wikipedia.org
==== Types of diabetes mellitus ==== Between 1850 and 1875, French researchers Apollinaire Bouchardat and E. Lancereux acknowledged a need for classification. They distinguished between those diabetics that were lean, had severe symptoms, poor outcomes, and pancreatic lesions at autopsy (diabetes maigre), and those that were overweight, presented later in life with a milder form of the disease and had a better prognosis if put on a low-calorie diet (diabetes gras). These descriptions are comparable to the two types identified by Ayurvedic physicians Sushruta and Charaka (400–500 AD), with one type being associated with youth and the other with being overweight. Harold Percival Himsworth established a clearer distinction in 1936, differentiating two types of diabetes based on sensitivity to insulin (both injected and pancreatic). In 1950, R. D. Lawrence observed that some diabetics were deficient in insulin and that some were not. Philip Hugh-Jones, while working in Jamaica in 1955, clarified Lawrence's classification and coined the terms "type 1" and "type 2" diabetes. He also noted a rarer variety observed in insulin-resistant youth (whose condition could not be placed into the two types). He called this third group "type J", where J stood for Jamaica. The terms type 1 and 2 were for some time forgotten. In 1976, they were revived and popularized by Andrew Cudworth after he discovered the link between type 1 diabetes and a specific genetic marker.
Bradbury AF, Finnie MD, Smyth DG (1982). "Mechanism of C-terminal amide formation by pituitary enzymes". Nature. 298 (5875): 686–8. Bibcode:1982Natur.298..686B. doi:10.1038/298686a0. PMID 7099265. S2CID 4324776. Bradbury AF, Smyth DG (1987). "Enzyme-catalysed peptide amidation. Isolation of a stable intermediate formed by reaction of the amidating enzyme with an imino acid". Eur. J. Biochem. 169 (3): 579–84. doi:10.1111/j.1432-1033.1987.tb13648.x. PMID 3691506. Glembotski CC (1985). "Further characterization of the peptidyl alpha-amidating enzyme in rat anterior pituitary secretory granules". Arch. Biochem. Biophys. 241 (2): 673–83. doi:10.1016/0003-9861(85)90594-6. PMID 2994573. Katopodis AG, Ping D, May SW (1990). "A novel enzyme from bovine neurointermediate pituitary catalyzes dealkylation of alpha-hydroxyglycine derivatives, thereby functioning sequentially with peptidylglycine alpha-amidating monooxygenase in peptide amidation". Biochemistry. 29 (26): 6115–20. doi:10.1021/bi00478a001. PMID 2207061. Murthy AS, Keutmann HT, Eipper BA (1987). "Further characterization of peptidylglycine alpha-amidating monooxygenase from bovine neurointermediate pituitary". Mol. Endocrinol. 1 (4): 290–9. doi:10.1210/mend-1-4-290. PMID 3453894. Murthy AS, Mains RE, Eipper BA (1986). "Purification and characterization of peptidylglycine alpha-amidating monooxygenase from bovine neurointermediate pituitary". J. Biol. Chem. 261 (4): 1815–22. doi:10.1016/S0021-9258(17)36013-1. PMID 3944110.
Apart from the failed Third Period policy in the early 1930s, Marxist–Leninists played an important role in anti-fascist resistance movements, with the Soviet Union contributing to the Allied victory in World War II. In accordance with the three-power Yalta Agreement (4–11 February 1945), the Soviet Union purged native fascist collaborators and these in collaboration with the Axis Powers from the Eastern European countries occupied by the Axis Powers and installed native Marxist–Leninist governments.
) within a single experiment. It consists of two cells which are enclosed in an adiabatic jacket. The compounds to be studied are placed in the sample cell, while the other cell, the reference cell, is used as a control and contains the buffer in which the sample is dissolved. The technique quantifies the heat released or absorbed during the binding process by incrementally adding one reactant (via a syringe) to another (in the sample cell) while maintaining constant temperature and pressure. Heat-sensing devices within the ITC detect temperature variations between two cells, transmitting this information to heaters that adjust accordingly to restore thermal equilibrium between the cells. This energy is converted into binding enthalpy using the information about concentrations of the reactants and the cell volume. Compared to other calorimeters, ITC does not require any correctors since there is no heat exchange between the system and the environment. ITC is also highly sensitive with a fast response time and benefits from modest sample requirements. While differential scanning calorimetry (DSC) can also provide direct information about the thermodynamic of binding interactions, ITC offers the added capability of quantifying the thermodynamics of metal ion binding to proteins.
The company's headquarters is the Starbucks Center in Seattle, Washington, United States, where 3,750 people worked as of 2023. The main building in the Starbucks complex in SODO, where the company leases 1.29 million square feet (120,000 m2) of space, was previously a Sears mail order distribution center until 1987. In 2026, Starbucks announced the long-term lease of 250,000 square feet (23,000 m2) for a regional office in Nashville, Tennessee.
Sources: en.wikipedia.org
PT-141 was the development code used for bremelanotide during its preclinical and early clinical programme. The peptide is now generally referred to by its international nonproprietary name.
The two compounds share the same cyclic core and are both non-selective melanocortin agonists. They differ chiefly at the C-terminus, where bremelanotide carries a free carboxylic acid and melanotan II a terminal amide.
Receptor binding profiles are well characterised in vitro, but the downstream pathway linking MC4R activation to behavioural effects is not fully mapped. Several intermediate neural circuits have been proposed without definitive confirmation.
It primarily activates specific subtypes in the melanocortin receptor family. These receptors are G protein-coupled and mediate signaling mainly within the central nervous system.